Bleomycin
- Generic Name
- Bleomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C55H84N17O21S3
- CAS Number
- 11056-06-7
- Unique Ingredient Identifier
- 40S1VHN69B
- Background
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
- Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
- Associated Conditions
- Hodgkin's Lymphoma, Malignant Pleural Effusion, Non-Hodgkin's Lymphomas, Squamous Cell Carcinoma (SCC), Teratocarcinoma, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma
- Associated Therapies
- Palliative Treatment
HD11 for Intermediate Stages
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
HD10 for Early Stages
- Conditions
- Interventions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1370
- Registration Number
- NCT00265018
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00225173
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 60
- Registration Number
- NCT00136565
- Locations
- 🇧🇪
Groupe d'Etude des Lymphomes de l'Adulte, Yvoir, Belgium
🇫🇷Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷Centre Hospitalier Robert Debré, Reims, France
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 138
- Registration Number
- NCT00135499
- Locations
- 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 854
- Registration Number
- NCT00003389
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 76
- Registration Number
- NCT00026208
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.